Collegium Pharmaceutical (COLL) Long-Term Deferred Tax (2021 - 2025)
Historic Long-Term Deferred Tax for Collegium Pharmaceutical (COLL) over the last 5 years, with Q3 2025 value amounting to $102.5 million.
- Collegium Pharmaceutical's Long-Term Deferred Tax rose 4133.0% to $102.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.5 million, marking a year-over-year increase of 4133.0%. This contributed to the annual value of $98.0 million for FY2024, which is 27333.1% up from last year.
- Per Collegium Pharmaceutical's latest filing, its Long-Term Deferred Tax stood at $102.5 million for Q3 2025, which was up 4133.0% from $92.0 million recorded in Q2 2025.
- Collegium Pharmaceutical's Long-Term Deferred Tax's 5-year high stood at $102.5 million during Q3 2025, with a 5-year trough of $24.0 million in Q4 2022.
- Its 5-year average for Long-Term Deferred Tax is $51.7 million, with a median of $32.4 million in 2024.
- Its Long-Term Deferred Tax has fluctuated over the past 5 years, first tumbled by 6931.14% in 2022, then skyrocketed by 27333.1% in 2024.
- Collegium Pharmaceutical's Long-Term Deferred Tax (Quarter) stood at $78.0 million in 2021, then plummeted by 69.31% to $24.0 million in 2022, then increased by 9.64% to $26.3 million in 2023, then soared by 273.33% to $98.0 million in 2024, then grew by 4.53% to $102.5 million in 2025.
- Its Long-Term Deferred Tax stands at $102.5 million for Q3 2025, versus $92.0 million for Q2 2025 and $91.7 million for Q1 2025.